Difference between revisions of "Fluvoxamine-venlafaxine"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
| info =
 
| info =
 
* {{theorSS}}
 
* {{theorSS}}
 +
{{review}}
  
 
}}
 
}}

Revision as of 15:44, 21 October 2015

Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from fluvoxamine to venlafaxine.[1] [2]

Nietinrijdenbord.png Stop fluvoxamine
  • Gradually reduce dosage of fluvoxamine to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • When a dosage of 50 mg/day is reached, stop administration.
Eenrichtingbord.png Start venlafaxine
  • No wash-out period is needed.
  • The next day: Start administration of venlafaxine in a normal dosage of 37,5 mg or 75 mg (slow release) /day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.